Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Chalcone derivative blocks Abeta impairment of PKA/CREB signaling

Jan. 8, 2009

GlaxoSmithKline reports on discovery of EP1 receptor antagonist for inflammatory pain

Jan. 8, 2009

FDA approves once-daily Ryzolt for moderate to moderately severe pain

Jan. 7, 2009

King provides update on Embeda NDA review

Jan. 7, 2009

Acura and King Pharmaceuticals submit NDA to FDA for Acurox anti-abuse opioid analgesic

Jan. 7, 2009

IGF-1 does not affect outcome measures in phase III amyotrophic lateral sclerosis trial

Jan. 7, 2009

New mgluR2 ligands/5-HT2A antagonists described in Abbott patent

Jan. 5, 2009

Urigen amends licence agreement with UCSD for URG-101

Jan. 5, 2009

FDA issues complete response letter to Ipsen for Dysport BLA in cervical dystonia

Jan. 5, 2009

Sosei reacquires commercialization rights to opioid analgesic AD-923 from Mundipharma

Jan. 5, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...